A prospective study of cognitive function in men with non-seminomatous germ cell tumors

Psycho-Oncology

Volumn 23, Issue 6, 2014, Pages 626-633

  Wefel, Jeffrey S ^a   Vidrine, Damon J ^a   Marani, Salma K ^a   Swartz, Richard J ^b   Veramonti, Tracy L ^c   Meyers, Christina A ^a   Hoekstra, Harald J ^d   Hoekstra Weebers, Josette E H M ^d,e   Gritz, Ellen R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b RICE UNIVERSITY   (United States)

^c Mentis Neuro Rehabilitation   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Integraal Kankercentrum Noord Nederland   (Netherlands)

Author keywords

chemotherapy; cognitive function; neurotoxicity; oncology; quality of life; testicular cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; CANCER ADJUVANT THERAPY; COGNITION; COGNITIVE DEFECT; FOLLOW UP; HUMAN; LEARNING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; NEUROPSYCHOLOGICAL TEST; NON SEMINOMATOUS GERMINOMA; PROSPECTIVE STUDY; PSYCHOMOTOR ACTIVITY; ADJUVANT CHEMOTHERAPY; ADOLESCENT; CASE CONTROL STUDY; DOSE RESPONSE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; PSYCHOLOGY; TESTICULAR NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUROPSYCHOLOGICAL TESTS; ORCHIECTOMY; PROSPECTIVE STUDIES; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 84902118039     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.3453     Document Type: Article

References (34)

1. Wefel JS, Vidrine DJ, Veramonti TL, et al,. Cognitive impairment in men with testicular cancer prior to adjuvant therapy. Cancer 2011; 117: 190-196.
2. Wefel JS, Lenzi R, Theriault R, et al,. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004; 101: 466-475.
3. Cimprich B, So H, Ronis DL, et al,. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology 2005; 14: 70-78. (Pubitemid 40124675)
4. Hermelink K, Untch M, Lux MP, et al,. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007; 109: 1905-1913. (Pubitemid 46668557)
5. Ahles TA, Saykin AJ, McDonald BC, et al,. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008; 110: 143-152. (Pubitemid 351793851)
6. Mohile SG, Lacy M, Rodin M, et al,. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol 2010; 75: 152-159.
7. Meyers CA, Byrne KS, Komaki R,. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995; 12: 231-235.
8. Seigers R, Schagen SB, Van Tellingen O, Dietrich J,. Chemotherapy-related cognitive dysfunction: current animal studies and future directions. Brain Imaging Behav 2013; DOI: 10.1007/s11682-013-9250-3
9. Seigers R, Fardell JE,. Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 2011; 35: 729-741.
10. Wefel JS, Lenzi R, Theriault RL, et al,. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004; 100: 2292-2299. (Pubitemid 38657875)
11. Wefel JS, Saleeba AK, Buzdar AU, et al,. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010; 116: 3348-3356.
12. Wefel JS, Vardy J, Ahles, T, et al,. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 2011; 12: 660-668.
13. Schagen SB, Boogerd W, Muller MJ, et al,. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 2008; 47: 63-70.
14. Gritz ER, Wellisch DK, Landsverk JA,. Psychosocial sequelae in long-term survivors of testicular cancer. Psycho-Oncology 1988; 6: 41-63.
15. Pedersen AD, Rossen P, Mehlsen MY, Pedersen CG, Zachariae R, von der Maase H,. Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 2009; 15: 296-301.
16. Skaali T, Fossa SD, Andersson S, et al,. A prospective study of neuropsychological functioning in testicular cancer patients. Ann Oncol 2011; 22: 1062-1070.
17. Travis LB, Beard C, Allan JM, et al,. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010; 102: 1114-1130.
18. Radloff LS,. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
19. Spielberger CD, Gorsuch RL, Lushene R, et al,. The State-Trait Anxiety Inventory. Consulting Psychologists Press: Palo Alto, 1983.
20. Zich JM, Attkisson CC, Greenfield TK,. Screening for depression in primary care clinics: the CES-D and the BDI. Int J Psychiatry Med 1990; 20: 259-277. (Pubitemid 20366033)
21. Geisser ME, Roth RS, Robinson ME,. Assessing depression among persons with chronic pain using the Center for Epidemiological Studies-Depression Scale and the Beck Depression Inventory: a comparative analysis. Clin J Pain 1979; 13: 163-170.
22. Green FL, Fritz AG, Balch CM, et al,. AJCC Cancer Staging Manual (6th edn), Springer: New York, 2002.
23. Group IGCC. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
24. Stewart A, Collins B, Mackenzie J, et al,. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psycho-Oncology 2008; 17: 122-130. (Pubitemid 351279862)
25. McSweeny AJ, Chelune GJ, Naugle RI, et al,. « T Scores for change»: an illustration of a regression approach to depicting change in clinical neuropsychology. Clin Neuropsychol 1993; 7: 300-312. (Pubitemid 23279991)
26. Sawrie SM, Marson DC, Boothe AL, et al,. A method for assessing clinically relevant individual cognitive change in older adult populations. J Gerontol B Psychol Sci Soc Sci 1999; 54: 116-124.
27. Green HJ, Pakenham KI, Headley BC, et al,. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002; 90: 427-432. (Pubitemid 36124778)
28. Ouimet LA, Stewart A, Collins B, et al,. Measuring neuropsychological change following breast cancer treatment: an analysis of statistical models. J Clin Exp Neuropsychol 2009; 31: 73-89.
29. van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S,. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-218. (Pubitemid 28114539)
30. Wechsler D,. Wechsler Adult Intelligence Scale-Revised. The Psychological Corporation: San Antonio, 1981.
31. Reitan RM,. Trail Making Test Manual for Administration and Scoring. Reitan Neuropsychology Laboratory: Tucson, 1992.
32. Brandt J,. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol 1991; 5: 125-142.
33. Benton AL, Hamsher K,. Multilingual Aphasia Examination. AJA Associates: Iowa City, 1983.
34. Trites RL,. Lafayette Grooved Pegboard Neuropsychological Test Manual. Royal Ottawa Hospital: Ottawa, 1977.